FDA Revokes Emergency Use Authorization for COVID-19 Drug Actemra
December 09, 2025
December 09, 2025
WASHINGTON, Dec. 9 (TNSFR) -- The U.S. Department of Health and Human Services Food and Drug Administration has revoked the emergency use authorization (EUA) for Actemra, a drug manufactured by Genentech Inc., South San Francisco, California.
The revocation became effective on Aug. 8, 2025, following the FDA's approval of a supplemental license that expands the drug's use for treating COVID-19.
The initial EUA for Actemra was issued to Genentech on June 24, 20 . . .
The revocation became effective on Aug. 8, 2025, following the FDA's approval of a supplemental license that expands the drug's use for treating COVID-19.
The initial EUA for Actemra was issued to Genentech on June 24, 20 . . .